Article ID Journal Published Year Pages File Type
5502333 Journal of Geriatric Oncology 2017 5 Pages PDF
Abstract
SBRT for early-stage NSCLC is the accepted standard of care in medically inoperable patients, though in many very elderly patients, dose is either de-intensified or withheld for concern of toxicity in the setting of advanced age and competing risks. In this study of our very elderly (≥ 80 years old) early-stage NSCLC patients, we highlight both the extremely high efficacy and tolerability (zero grade 2 or above toxicities) associated with definitive intent SBRT.
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Ageing
Authors
, , , , , ,